Abstract: The invention relates to methods of treating shock in a subject by administering a pharmaceutically effective amount of androstenetriol (AET), androstenediol (AED) or derivatives thereof to a subject suffering from or exhibiting the symptoms of shock. In one particular embodiment, the subject is suffering from hemorrhagic shock. The invention also relates to methods of preventing shock in a subject at risk suffering from shock by administering a pharmaceutically effective amount of androstenetriol or a derivative thereof to the subject, prior to or immediately at the onset of the first symptoms of shock. In one particular embodiment, the subject is at risk suffering from hemorrhagic shock.

Abstract: The invention relates to the field of pharmaceuticals for tumor-inhibitory effects. The 5-androstene 3?,17? diol (?AED) and 5-androstene 3?,17? diol (?AED), their esters and ethers, are taught herein to achieve tumor-inhibiting effect. The invention also relates to the field of pharmaceuticals for tumor-inhibitory effects and the use of 5-androstene 3?,7?,17? triol (?AET), 5-androstene 3?,7?,17? triol (?AET or 17?-AET) and their esters and ethers, are taught herein to achieve tumor-inhibiting effect.

Abstract: The present invention provides an improved means for regulating the immune response, for ameliorating effects of stress, and for avoiding untoward effects of chemotherapy or exposure to irradiation by administration of androstenediol (AED) and androstenetriol (AET). The improved means of regulating immune response can be utilized in treating infectious diseases and immune diseases such as diabetes and chronic fatigue syndrome, both diseases now considered to be immune response related syndromes.